Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early postoperative changes with different priming solutions in open-heart surgery.

H Lindberg, J L Svennevig, K Vatne

    Scandinavian Journal of Thoracic and Cardiovascular Surgery
    |January 1, 1985
    PubMed
    Summary

    Dextran 70 can replace human plasma in open-heart surgery priming solutions. This study found no major differences, suggesting dextran 70 offers a safer, cost-effective alternative for cardiac surgery patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047).

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Assessment of hospital surge capacity using the MACSIM simulation system: a pilot study.

    European journal of trauma and emergency surgery : official publication of the European Trauma Society·2016
    Same author

    In vitro and in vivo evaluation of Dideco's paediatric cardiopulmonary circuit for neonates weighing less than five kilograms.

    Perfusion·2010
    Same author

    Is it possible to predict outcome in pulmonary ECMO? Analysis of pre-operative risk factors.

    Perfusion·2008
    Same author

    Transportation of critically ill patients on extracorporeal membrane oxygenation.

    Perfusion·2008
    Same author

    Evaluation of oxygenators and centrifugal pumps for long-term pediatric extracorporeal membrane oxygenation.

    Perfusion·2008

    Area of Science:

    • Cardiovascular Surgery
    • Anesthesiology
    • Biomaterials

    Background:

    • Human plasma is a limited resource and carries disease transmission risks.
    • Priming solutions are critical for cardiopulmonary bypass during open-heart surgery.
    • Exploring dextran 70 as a plasma substitute is essential for patient safety and resource management.

    Purpose of the Study:

    • To evaluate the clinical, hemodynamic, metabolic, and roentgenologic effects of substituting dextran 70 for human plasma in cardiopulmonary bypass priming solutions.
    • To compare the outcomes of open-heart surgery patients receiving dextran 70 versus human plasma in the priming solution.
    • To assess the safety and efficacy of dextran 70 as a plasma replacement in cardiac surgery.

    Main Methods:

    • A prospective study involving 20 patients undergoing elective coronary artery disease surgery.

    Related Experiment Videos

  • Patients were divided into two groups (n=10 each): one receiving human plasma, the other dextran 70 in the priming solution.
  • Comprehensive monitoring of clinical, hemodynamic, metabolic, and roentgenologic parameters for 48 hours post-surgery.

    • Main Results:

    • No significant major differences were observed between the dextran 70 and human plasma groups.
    • The dextran 70 group exhibited a potentially lower pulmonary capillary wedge pressure, suggesting improved left ventricular performance.
    • Hemodynamic and metabolic parameters showed comparable results between the two priming solutions.

    Conclusions:

    • Dextran 70 is a viable and safe alternative to human plasma in priming solutions for open-heart surgery.
    • The use of dextran 70 may offer advantages in left ventricular performance and reduce risks associated with human plasma.
    • Dextran 70 presents a cost-effective and readily available option for cardiopulmonary bypass priming, addressing limitations of human plasma.